--Study Results Demonstrating Trend Toward Improvement in 30-Day All-Cause Mortality Presented at ESC Congress 2012-
MUNICH and WAYNE, N.J., Aug. 27, 2012 /PRNewswire/ -- MAQUET Cardiovascular LLC, the market leader in intra-aortic balloon counterpulsation therapy, today announced 30-day results from the large, randomized, multicenter IABP- SHOCK II ("SHOCK II") clinical trial in patients with acute myocardial infarction (AMI) who were in cardiogenic shock and undergoing early revascularization. The findings showed that use of intra-aortic balloon counterpulsation (IABC) therapy was associated with an observed improvement in all-cause mortality at 30 days, but the trial did not meet the pre-specified 12 percent improvement in survival endpoint compared with standard medical therapy. In the trial, IABC therapy was shown to be safe without any increase in complications compared to the control group. The findings were presented in the Hot Line II: Late-Breaking Trials on Interventions session during the European Society of Cardiology (ESC) Congress 2012 in Munich.
"Patients in cardiogenic shock are critically ill and require aggressive treatment measures," said Marc Cohen, M.D., chief of the division of cardiology at Newark Beth Israel Medical Center in Newark, N.J., and professor of medicine at the Mount Sinai School of Medicine in New York. "The results of the SHOCK II trial demonstrated unparalleled safety with IABC therapy in this patient population, and I believe it would be premature, without further exploration of the data, to determine which patients are best served with IABC therapy."
He added, "Previous clinical trials in other patient populations, including those undergoing high-risk percutaneous coronary intervention [PCI], have shown that the benefits of IABC therapy can be seen beyond 30 days. It is important that we wait and assess the six-month and 12-month mortality data from IABP-SHOCK II before making definitive conclusions about the use of IABC therapy in cardiogenic shock patients."
IABC therapy, which reduces the workload of the heart and improves perfusion of the coronary arteries, has been the standard of care for critically ill patients requiring hemodynamic support for more than 40 years, with more than 1 million patients treated. Patients who have experienced an AMI that is complicated by cardiogenic shock and who are undergoing early revascularization are routinely given an intra-aortic balloon pump during an elective procedure to improve heart function. Results from multiple patient registries have shown a significant reduction in mortality in AMI patients with cardiogenic shock in hospitals that regularly used IABC therapy to treat patients regardless of patients' baseline characteristics, hospital-related factors, treatment or procedure-related factors, such as percutaneous coronary intervention (PCI).
SHOCK II Study Design and Results
SHOCK II was a prospective trial that evaluated the benefits of IABC therapy compared with standard medical therapy on all-cause mortality at 30 days in AMI patients experiencing cardiogenic shock who were undergoing early revascularization. The trial was conducted at 37 clinical sites in Germany and randomized 600 patients (301 to IABC and 299 to control).
Although the trial did not show a statistically significant all-cause mortality benefit at 30 days, the mortality curves for the two treatment regimens began to diverge slightly at 20-30 days. Thirty days after randomization, the mortality rate was 39.7 percent for the IABC patient group and 41.3 percent for the control group. The trial is continuing to follow patients and will report all-cause mortality results at six and 12 months.
The SHOCK II trial was partially funded by an unrestricted grant from MAQUET.
About Cardiogenic Shock
Cardiogenic shock results when the ventricles of the heart fail to pump effectively, resulting in insufficient perfusion of tissue to meet the heart muscle's demands for oxygen and nutrients. It is a major and frequently fatal complication of a variety of acute and chronic disorders, occurring most commonly following AMI.[i] In the United States, the incidence rate of cardiogenic shock ranges from 5-10 percent in patients with AMI. The overall incidence is higher in men than in women because of the increased prevalence of coronary artery disease in males, with females accounting for 42 percent of patients with cardiogenic shock. For adults, the median age for cardiogenic shock is 65-66 years.[ii]
About MAQUET
As a trusted partner for hospitals and clinicians since 1838, Maquet is a global leader in medical systems that advance surgical interventions, cardiovascular procedures and critical care. Maquet develops and designs innovative products and therapeutic applications for the operating room, hybrid OR/Cath lab, intensive care unit and patient transport within acute care hospitals, improving outcomes and quality of life for patients.
Cardiovascular specialties include intra-aortic balloon counterpulsation therapy for cardiac assist; coronary artery bypass surgery; aortic and peripheral vascular surgery; and extracorporeal circulation.
The Critical Care portfolio includes market-leading intensive care ventilators and anesthesia machines.
Maquet also equips Surgical Workplaces with critical infrastructure such as flexible room design for OR and ICU; OR tables; lights and ceiling supply units; and OR integration for image data management.
Maquet is a subsidiary of the publicly listed Swedish Getinge Group. In 2011, Maquet generated nearly 1.4 billion Euro which is more than half of the Group's annual revenue of 2.4 billion Euros. The Getinge Group has 13,000 employees worldwide, including around 6,000 Maquet employees in 50 international sales and service organizations, as well as a network of more than 280 sales representatives. For more information please visit www.maquet.com and www.getingegroup.com.
MAQUET – The Gold Standard
[i] http://emedicine.medscape.com/article/152191-overview
[ii] http://emedicine.medscape.com/article/152191-overview#a0156
SOURCE MAQUET Cardiovascular LLC